Although it has been suggested that a well‐designed and powered clinical trial could show that topiramate is effective for IBD, there is no association of SCN1A with IBD in the GWAS catalog (with approximately 29 000 cases in the largest study cohort) [91]. This evidence concerns the gene SCN1A and inflammatory bowel disease.